



AKI

AKI

- AKI is a clinical manifestation of underlying diseases
- Acute impairment of kidney function, resulting in the retention of urea and other nitrogenous waste products and metabolic derangement (dysregulation of extracellular volume and electrolytes)
- In patients <18 years, stage 3 AKI is also defined by KDIGO as a decrease in estimated glomerular filtration rate (eGFR) to <35 mL/min/1.73 m².

	RIFLE^[1]	AKIN^[2]	KDIGO^[3]
Diagnostic criteria*			
		Increase in serum creatinine of ≥ 0.3 mg/dL or $\geq 50\%$ within 48 hours OR Urine output of < 0.5 mL/kg/hour for > 6 hours	Increase in serum creatinine of ≥ 0.3 mg/dL within 48 hours or $\geq 50\%$ within 7 days OR Urine output of < 0.5 mL/kg/hour for > 6 hours

Staging criteria			
Risk (RIFLE) or stage 1 (AKIN/KDIGO)	Increase in serum creatinine to 1.5 times baseline OR Urine output of <0.5 mL/kg/hour for 6 to 12 hours	Increase in serum creatinine of ≥ 0.3 mg/dL or to 150 to 200% baseline OR Urine output of <0.5 mL/kg/hour for 6 to 12 hours	Increase in serum creatinine of ≥ 0.3 mg/dL or 1.5 to 1.9 times baseline OR Urine output of <0.5 mL/kg/hour for 6 to 12 hours
Injury (RIFLE) or stage 2 (AKIN/KDIGO)	Increase in serum creatinine to 2 times baseline OR Urine output of <0.5 mL/kg/hour for 12 to 24 hours	Increase in serum creatinine to 200 to 300% baseline OR Urine output of <0.5 mL/kg/hour for 12 to 24 hours	Increase in serum creatinine to 2 to 2.9 times baseline OR Urine output of <0.5 mL/kg/hour for 12 to 24 hours
Failure (RIFLE) or stage 3 (AKIN/KDIGO)	Increase in serum creatinine to 3 times baseline OR Urine output of <0.3 mL/kg/hour for >24 hours or anuria for >12 hours	Increase in serum creatinine to >300% baseline OR Urine output of <0.3 mL/kg/hour for >24 hours or anuria for >12 hours	Increase in serum creatinine of ≥ 0.3 mg/dL to ≥ 4 mg/dL [†] OR Urine output of <0.3 mL/kg/hour for ≥ 24 hours or anuria for ≥ 12 hours

Loss (RIFLE)	Need for kidney replacement therapy for >4 weeks	Initiation of kidney replacement therapy	Need for kidney replacement therapy for >3 months
End stage (RIFLE)	Need for kidney replacement therapy for >3 months	Initiation of kidney replacement therapy	

AKI

- The KDIGO define AKI as follows:
 - Increase in serum creatinine by **≥ 0.3 mg/dL within 48 hours**, or
 - Increase in serum creatinine **to ≥ 1.5 times baseline** occurred within the prior **seven days**, or
 - Reduction in urine volume **< 0.5 mL/kg/hour** for six hours

KDIGO Staging

Stage	S creatinine	Urine output
1	1.5-1.9 times baseline or ≥ 0.3 mg/dl increase	<0.5 ml/kg/hour for 6-12 hours
2	2.0-2.9 times baseline	<0.5 ml/kg/hour for ≥ 12 hours
3	3 times baseline or S creatinine ≥ 4 mg/dl	<ul style="list-style-type: none">◆ <0.3 ml/kg/hr for ≥ 24 hours or◆ Anuria for ≥ 12 hours



KDIGO STAGE

Stage	Serum Creatinine	Urine output
Stage I	Increase in serum creatinine of ≥ 0.3 mg/dL or 1.5 to 1.9 times baseline	Urine output of < 0.5 mL/kg/hour for 6 to 12 hours
Stage II	Increase in serum creatinine to 2 to 2.9 times baseline	Urine output of < 0.5 mL/kg/hour for 12 to 24 hours
Stage III	Increase in serum creatinine to ≥ 3 times baseline OR, Increase in serum creatinine of ≥ 0.3 mg/dL to ≥ 4 mg/Dl	Urine output of < 0.3 mL/kg/hour for ≥ 24 hours or anuria for ≥ 12 hours OR, Initiation of kidney replacement therapy

Causes of AKI

Pre-renal

Renal/Intrinsic

Postrenal

Prerenal causes

Hypovolemia: Acute diarrhoea, vomiting, burn, sepsis, haemorrhage, diabetic ketoacidosis

Congestive heart failure

Perinatal asphyxia

Third space loss: septicemia, nephrotic syndrome

Drugs: Diuretics, ACE inhibitors

Renal/Intrinsic causes

- Vascular: HUS, Vasculitis, renal vein thrombosis
- Tubular
 - Acute tubular necrosis (ATN)
 - Wasp sting, snake venom
 - Nephrotoxic drug e.g. diethyl glycol, methanol
 - Tumor lysis syndrome (uric acid crystals tubular obstruction)
- Glomerulonephritis
 - Post infectious GN
 - Membranous proliferative GN
 - Systemic disorder: SLE, Henoch-Schonlein syndrome, Microscopic polyangiitis
- Interstitial: Interstitial nephritis, pyelonephritis
- Medications: aminoglycosides, radiocontrast, amphotericin B, ACE inhibitor, Indomethacin, NSAIDs

Post renal causes

- Urinary obstruction:
 - Posterior urethral valves,
Urethral stricture
 - Bilateral UPJ obstruction
 - Blood clot in the urinary tract
 - **Neurogenic bladder**

Pathogenesis

- Rapid decline in GFR which results in
 - Accumulation of nitrogenous wastes in the body
 - Elevation of blood urea, creatinine, blood urea nitrogen (BUN)
- Impairment of water, electrolytes and acid-base balances
 - Dyselectrolytaemia e.g. hyperkalaemia
 - Acid-base imbalance e.g. metabolic acidosis
 - Fluid overload, hypertension

Clinical features

Hallmark of AKI

- Scanty urine (oliguria)
- Complete cessation of urine (anuria)

Other manifestations

- Vomiting
- Convulsions



Approach of AKI

- History
 - H/o anuria, oliguria, vomiting, or blood loss
 - Assessment of fluid intake in the previous 24 hours
 - History to find out the causes –
 - Fluid loss e.g. diarrhoea, severe vomiting
 - Pre-existing kidney disease e.g. AGN, NS
 - Ingestion of nephrotoxic drug e.g. diethyl glycol in paracetamol, aminoglycoside

Examination

Features of fluid overload e.g.

- Facial puffiness, oedema, hypertension
- Heart failure (hepatomegaly, pulmonary oedema)

Features of severe dehydration e.g.

- Drowsiness
- Skin pinch not going back quickly

Toxic features of AKI e.g. unconsciousness, arrhythmia, vomiting, convulsion

Flank: Palpable renal mass (renal vein thrombosis)

Urinary bladder: Palpable (PUV)

Haemodynamic status e.g. pulse, BP, capillary refill time

Investigations

CBC: Hb (reduced), Leukopenia (sepsis), Thrombocytopenia (HUS)

Blood biochemistry

- S creatinine, urea, BUN: Raised
- S electrolytes: High K⁺, low HCO₃⁻ Low Na⁺
- S calcium (low), Phosphate (high)
- ABG: Metabolic acidosis

Urine R/M/E: RBC, protein, crystal, granular cast

Blood: ASO titre, C3 , C4, ANA, Anti-ds DNA, Ab to GBM

Investigations



Chest X-Ray: Cardiomegaly,
pulmonary congestion, pleural
effusion



Renal ultrasound
scan:

To rule out UTI
obstruction
Kidney morphology



Renal biopsy



ECG

Treatment

01

Hospitalize the child

02

Counsel the parents about the illness

03

Discontinue nephrotoxic drug, if any

04

Introduce, a catheter when suspected PUV, and

05

Monitor urine output

Treatment



FLUID
RESUSCITATION




TREATMENT OF THE
UNDERLYING
CAUSE OF AKI



MANAGEMENT OF
ASSOCIATED
CONDITIONS



NUTRITION
SUPPORT



DIALYSIS



RENAL
REPLACEMENT
THERAPY

Fluid resuscitation

No volume overload or CCF

- NS, 20 mL/kg over 30 minutes (hypovolemic patient generally void within 2 hours)

Hypotension due to sepsis

- IV fluid along with continuous infusion of **vasopressor**


Adequate circulatory volume is established/pulmonary oedema

- O2 inhalation, propped-up position
- Furosemide (2-4 mg/kg)- single IV

No urine output with this single dose of frusemide

- Continuous diuretic infusion ± Injection Dopamine (2-3 g/kg/min) for renal cortical blood flow

Fluid resuscitation



- If still no response to the diuretic challenge
 - Stop giving diuretics
 - Restrict fluid to 400 mL/m^2 /day (insensible loss) + previous day urine output
 - Replace any external loss (blood, GIT) meticulously with appropriate fluid
 - Readjust fluid allocation, if volume overload
 - Monitor intake-output, body weight and S chemistries daily

Treatment of underlying causes

- Treat underlying causes if any



Management of associated conditions

- Hyperkalemia
 - Calcium gluconate 10% IV 0.5-1 ml/kg over 5-10 minutes
 - Salbutamol 5-10 mg nebulized
 - Sodium bicarbonate 7.5% 1-2 ml/kg over 15 minutes
 - Dextrose 10% 0.5-1 g/kg and insulin 0.1-0.2 U/kg IV
 - Calcium or sodium resonium (Kayexalate) 1 g/kg/day

Management of associated conditions

- Metabolic acidosis:
 - Sodium bicarbonate (1ml/kg), IV if less than 18 mEq/l
- Hypertension
 - Asymptomatic cases: Isradipine (0.05-0.15 mg/kg/dose) QID, nifedipine
 - Symptomatic cases e.g. hypertensive encephalopathy, Na Nitroprusside (0.5-10 µg/kg/min) or Labetalol (0.25-3.0 mg/kg/hour) by infusion under the supervision
 - Others: Amlodipine (0.1-0.6 mg/kg/day) BID
 - Labetelol (4-40 mg/kg/day)

Management of associated conditions

- Hyponatremia
 - Fluid restriction
 - Sensorial alteration or seizures: 3% saline 6-12 ml/kg over 30-90 minutes
- Severe anemia
 - Packed cells 3-5 ml/kg; consider exchange transfusion
- GIT bleeding: IV Omeprazole
- Hypocalcaemia:
 - Lowering s PO₄ by phosphate binder will help to improve s calcium.
Injection Calcium gluconate should not be given until tetany (1-2 ml/kg)
- Hyperphosphatemia: Dietary restriction

Nutritional support

- Encourage a high-calorie diet, rich in carbohydrates and fat to reduce protein catabolism
- Protein: 1-1.2 g/kg in infant, 0.8-1.2 g/kg in others
- Calories: 60-80 cal/kg/day
- Vitamin, and micronutrient supplements
- Restrict extra salt intake
- Avoid foods rich in potassium e.g. citrus fruits, tomato paste, chocolates and potato chips

Dialysis

Indications

- ◆ Anuria/oliguria
- ◆ Volume overload with evidence of hypertension and/or pulmonary edema refractory to diuretic therapy
- ◆ Persistent hyperkalaemia
- ◆ Severe metabolic acidosis, unresponsive to medical management
- ◆ Uremia (encephalopathy, pericarditis, neuropathy)
- ◆ Calcium: Phosphorus imbalance, with hypocalcemic tetany that cannot be controlled by other measures
- ◆ Inability to provide adequate nutritional intake because of the need for severe fluid restriction

References

Ghai Essential
Pediatrics-10th
edition

Nelson Essential
of Pediatrics-24th
edition

UpToDate



Thank You